Scientific Board

Synergix Ltd. has established a Scientific Advisory Board comprised of the key thought leaders in the areas of drug design, molecular modeling and medicinal chemistry.

  • Prof. Gordon M. Crippen University of Michigan, Ann Arbor, USA
  • Prof. Toshio Fujita Fujitsu Kansai Laboratory, Osaka, Japan
  • Prof. Johann Gasteiger Erlangen University, Erlangen, Germany
  • Dr. Konrad Koehler Karo Bio Novum Ltd., Huddinge, Sweden
  • Dr. Patrick Y. Lam Bristol-Myers Squibb Company, Wilmington, Delaware, USA
  • Prof. Alexander Levitzki The Hebrew University, Jerusalem, Israel
  • Dr. Gerald M. Maggiora Pharmacia & Upjohn, Kalamazoo, Michigan, USA
  • Prof. Raphael Mechoulam The Hebrew University, Jerusalem, Israel
  • Prof. Laszlo Pallos Hungarian Chemical Society, Budapest, Hungary
  • Prof. Robert S. Pearlman University of Texas at Austin, Texas, USA
  • Prof. Roberto Pellicciari University di Perugia, Perugia, Italy
  • Prof. Pierre Potier Institut de Chimie des Substances Naturelles CNRS, Gif, France
  • Dr. Tomi K. Sawyer Ariad Pharmaceuticals Inc., Cambridge, Massachusetts, USA
  • Dr. Jonathan M. Schapiro Stanford University School of Medicine, California, USA
  • Prof. Harold Scheraga Cornell University, Ithaca, New York, USA
  • Prof. Brian Shoichet Northwestern University Medical School, Chicago, Illinois, USA
  • Prof. Hendrik Timmerman Leiden University, Amsterdam, The Netherlands
  • Prof. Jan P. Tollenaere Janssen Research Foundation, Beerse, Belgium
  • Prof. David J. Triggle State University of New York, Buffalo, New York, USA
  • Prof. Jacques Weber University of Geneva, Geneva, Switzerland
  • Prof. Paul A. Wender Stanford University, Stanford, California, USA
  • Dr. Alexander Wlodawer National Cancer Institute, Frederick, Maryland, USA
  • Prof. Shoshana Wodak University of Brussels, Brussels, Belgium
  • Prof. Albert Zilkha The Hebrew University, Jerusalem, Israel